Comorbidities significantly impact patients’ preferences for psoriasis treatments

Schmieder, Astrid; Schaarschmidt, Marthe‐Lisa; Umar, Nasir; Terris, Darcy D.; Goebeler, Matthias; Goerdt, Sergij; Peitsch, Wiebke K.

doi:10.1016/j.jaad.2011.08.023

Cited by 49 publications

(47 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1,2 To help patients better align treatment choices with their personal values, the specifics of patient treatment preferences must be more elaborately embedded into the design of PDAs. 3,4 We undertook detailed assessment of psoriasis patients’ treatment decision-making experiences to discover key patient preferences that can be incorporated into subsequent psoriasis PDA design.…”

Section: To the Editormentioning

confidence: 99%

Patients With Psoriasis and Personalized Trade-offs in Treatment Decisions—Lessons Learned From Focus Groups

Kim

Ortenzio

et al. 2016

JAMA Dermatol

View full text Add to dashboard Cite

Section: To the Editormentioning

confidence: 99%

Patients With Psoriasis and Personalized Trade-offs in Treatment Decisions—Lessons Learned From Focus Groups

Kim

Ortenzio

et al. 2016

JAMA Dermatol

View full text Add to dashboard Cite

“…Comorbidities would also seem to have less influence on patients' preferences, although those who are depressed are more concerned with cost and duration of therapy, while those with cardiovascular disease are more concerned with side effects than with the magnitude of benefit [5].…”

Section: Discussionmentioning

confidence: 99%

Patient preferences for psoriasis treatment: process characteristics considered more important than outcome attributes

Meredith

Ormerod

2012

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

In a recent paper by Schaarschmidt et al., patients with moderate-to-severe psoriasis completed a conjoint analysis survey (discrete choice experiment) to determine which factors had influenced their choice of treatment, and the relative importance of each factor. They also assessed how socioeconomic and demographic factors affected patient choice. Using relative importance scores, treatment location was found to be the more important attribute to patients, followed by probability of benefit and method of delivery.

show abstract

“…Psoriasis, e.g. is a chronic inflammatory skin disease affecting about 2% of the world population [75]. It is mainly a T-cell-and dendritic cell-mediated disease, where plasmacytoid dendritic cells or Th17 cells recognize epidermal antigens [76,77].…”

Section: Macrophages In Obesity and The Link To Insulin Resistance Anmentioning

confidence: 99%

Macrophage activation in human diseases

Schultze

Schmieder

Goerdt

2015

Seminars in Immunology

Self Cite

110

View full text Add to dashboard Cite

Comorbidities significantly impact patients’ preferences for psoriasis treatments

Cited by 49 publications

References 47 publications

Patients With Psoriasis and Personalized Trade-offs in Treatment Decisions—Lessons Learned From Focus Groups

Patients With Psoriasis and Personalized Trade-offs in Treatment Decisions—Lessons Learned From Focus Groups

Patient preferences for psoriasis treatment: process characteristics considered more important than outcome attributes

Macrophage activation in human diseases

Contact Info

Product

Resources

About